Evaluation of the antitumor activity of rifamycin SV.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use; D002279:Carcinoma 256, Walker / Q000188:drug therapy*; D002460:Cell Line / Q000187:drug effects; D046508:Culture Techniques; D005021:Ethylamines / Q000627:therapeutic use; D005449:Fluorenes / Q000627:therapeutic use; D007372:Interferons / Q000096:biosynthesis; D007659:Ketones / Q000627:therapeutic use; D007939:Leukemia L1210 / Q000188:drug therapy*; D007942:Leukemia, Experimental / Q000188:drug therapy*; D051379:Mice; D011070:Poly I-C / Q000627:therapeutic use; D051381:Rats; D012293:Rifampin / Q000627:therapeutic use*
D000903:Antibiotics, Antineoplastic; D000998:Antiviral Agents; D005021:Ethylamines; D005449:Fluorenes; D007659:Ketones; D007372:Interferons; D011070:Poly I-C; D012293:Rifampin